Base to Base biotech podcast 21: Elix drug discovery platform, and CytoAgents on CAR-T, CRS and the FDA

Base to Base Biotech di Jim Cornall

Note sull'episodio

This week, we talk about drug discovery with Shinya Yuki, co-founder and CEO of Elix Inc., and Teresa Whalen, CEO of CytoAgents, about CAR-T therapies, cytokine release syndrome, and the FDA.

Interview times:

03:53 Elix

20:58 CytoAgents

Elix drug discovery platform

AI drug discovery company Elix, Inc. and the Life Intelligence Consortium (LINC) have announced that for the first time in the world, an AI drug discovery platform has been commercialized that incorporates multiple AI models trained using federated learning on data provided by 16 pharmaceutical companies.

The key to AI drug discovery lies in high-quality and sufficiently large datas ... 

 ...  Leggi dettagli
Parole chiave
biotechbiotechnologyartificial intelligenceAIdrug discoveryCAR-Tcytokine release syndromeCytoAgentsElix